Israele - ebraico - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

Israele - ebraico - Ministry of Health

kamada ltd - immunoglobulin normal human 5 %w/v - liquid - immunoglobulins, normal human, for intravascular adm. - replacement therapy in: primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia common variable immunodeficiency severe combined immunodeficiency wiskott aldrich syndrome myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections. children with congenital aids and recurrent infections. immunomodulation: idiopathic thrombocytopenic purpura (itp) in children or adults at high risk of bleeding spontaneously or prior to surgery to correct the platelet count guillain barre syndrome and kawasaki disease. allogeneic bone marrow transplantation.

Israele - ebraico - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

Israele - ebraico - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

Israele - ebraico - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - pregnancy/other obstetric conditions, suppression of rh immunization in non-sensitized rh0 (d) negative women delivering an rh0 positive baby or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions threatened abortion associated with maternal bleeding amniocentesis chorionic villus sampling ruptured tubal pregnancy and significant abdominal trauma. kam rh0 -d im should be given within 72 hours of the event. it may be given even after up to one month although efficacy may be somewhat reduced.transfusion: suppression of rh isoimmunization in rh0 (d) antigen-negative patients transfused with rh0 (d) antigen-positive rbcs of blood components containing rh0 (d) antigen-positive rbcs . initate treatment within 72 hours of exposure.

Israele - ebraico - Ministry of Health

csl behring ltd., israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - prophylaxis of rh (d) immunisation in rh (d)-negative women: anti-d immune globulin is administered for the prevention of rh (d) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. treatment is not necessary when it is assured that the child or the father are rh (d)- negative. criteria for a rhesus-incompatible pregnancy and the administration of anti-d immune globulin are : a) the mother is rh (d) -negative b) the child is either rh (d)-positive rh (d)weak - positive or its rhesus type is not known. routine antepartum prophylaxis : to prevent rh (d) immunisation due to spontaneous fetomaternal haemorrhage (fmh) during the last trimester of pregnancy. postpartum prophylaxis to prevent rh (d) immunisation of the rh (d)-negative mother following delivery of a rh (d)-positive child. complications of pregnancy: interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

Israele - ebraico - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg / 1 ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - suppression of rh immunization in non-sensitized rho(d) negative women delivering an rh positive baby, or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions, threatened abortion associated with maternal bleeding amniocentesis, chorionic villus sampling ruptured tubal pregnancy, and significant abdominal trauma. kam-rho should be given within 72 hours of event. immune thrombocytopenic purpura (itp): rho (d)-positive adults with chronic itp, children with chronic or acute itp, and patients with thrombocytopenia secondary to hiv infection in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage.

Israele - ebraico - Ministry of Health

lapidot medical import and marketing ltd - anti-d immunoglobulins 5000 iu/vial - powder for solution for injection - anti-d (rh) immunoglobulin - prevention of the hemolytic disease of the newborn and treatment of immune thrombocytopenic purpura (itp).

Israele - ebraico - Ministry of Health

novartis israel ltd - tisagenlecleucel - tisagenlecleucel

Israele - ebraico - Ministry of Health

amgen europe b.v. - romiplostim - אבקה להכנת תמיסה לזריקה - romiplostim 250 mcg/vial - romiplostim - romiplostim - nplate is indicated for the treatment of thrombocytopaenia in adult patients with chronic immune (idiopathic) thrombocytopaenic purpura (itp)- who are non-splenectomised and have had an inadequate response, or are intolerant, to both corticosteroids and immunoglobulins;-who are splenectomised and have had an inadequate response to splenectomy